Abstract | OBJECTIVE: To study the expression of germinal center B-cell (GCB)/activated B-cell like-related proteins to get optimal stratification of diffuse large B-cell lymphoma (DLBCL) patients, and correlate this with the established clinical and laboratory parameters. METHODS: RESULTS: Patients were classified as GCB group (17 patients) and non-GCB group (13 patients). We found a statistically significant association between non-GCB phenotype and performance status (PS) more than 1, high lactate dehydrogenase (LDH) level, advanced international prognostic index (IPI), and poor patient outcome. Non-GCB phenotype, high LDH level, and PS more than 1 were all associated with increased mortality risk. The median survival time was 46.9 months in group A compared to 19.6 months in group B (hazard ratio[HR]=3.30; 95% confidence interval [CI]=0.52-21.10). Using multivariate Cox regression analysis, non-GCB phenotype was found to be the most predicting factor (HR=6.07; 95% CI=1.6-22.9; p=0.008). CONCLUSION: The subclassification of DLBCL into GCB and non-GCB groups using immunohistochemistry may be useful for identifying those patients whose prognosis is so poor that more aggressive therapy can be given at the time of diagnosis.
|
Authors | Abeer A Saad, Nahla M Awed, Zeinab M Abdel-Hafeez, Gihan M Kamal, Hala M Elsallaly, Amal I Alloub |
Journal | Saudi medical journal
(Saudi Med J)
Vol. 31
Issue 2
Pg. 135-41
(Feb 2010)
ISSN: 0379-5284 [Print] Saudi Arabia |
PMID | 20174727
(Publication Type: Journal Article)
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Female
- Humans
- Immunohistochemistry
- Lymphoma, Large B-Cell, Diffuse
(classification, drug therapy, pathology)
- Male
- Middle Aged
- Prognosis
|